Current Edition


Adicet data hints at early promise for ‘gamma delta’ cell therapy

Dive Brief: Adicet Bio on Thursday reported updated results from an early-stage study testing a blood cancer treatment that harnesses gamma delta T cells, an …

Continue Reading →

Bayer backs out of Atara cell therapy deal

Dive Brief: Bayer plans stop developing cancer cell therapies with Atara Biotherapeutics, informing the California biotech company that it will terminate a research collaboration deal …

Continue Reading →

Versant-backed startup launches with plans to broaden cell therapy’s reach

Stem cell transplants can effectively cure a wide range of diseases, from blood cancers to rare genetic disorders. They’ve been used for decades and are …

Continue Reading →

Novartis turns cell therapy skill into contract manufacturing deal

Dive Brief: Novartis will manufacture an experimental cancer cell therapy for the small Philadelphia-based Carisma Therapeutics in a deal that marks another early step in …

Continue Reading →

Pfizer’s big bet on mRNA, Biogen ‘proven wrong’ on Aduhelm price and the next cell therapies

Biotechnology stocks ended the first day of the J.P. Morgan Healthcare Conference in the green, but only barely. By Monday afternoon, a closely followed index of …

Continue Reading →

Allogene cleared by FDA to resume ‘off the shelf’ cancer cell therapy trials

The Food and Drug Administration has cleared Allogene Therapeutics to resume testing its cancer cell therapies after determining the company’s technology wasn’t to blame for …

Continue Reading →

Takeda reels in a cell therapy research partner with ‘build-to-buy’ deal

Takeda, which has made cell and gene therapy a research focus, is turning to partnerships and acquisitions to help fill out its pipeline. In addition …

Continue Reading →

The International Society for Stem Cell Research brings researchers together in Melbourne

The conference is the world’s largest stem cell meeting and will attract more than 2,500 delegates from 60 countries, delivering around $13 million in economic …

Continue Reading →

Celonic AG Appoints Soenke Brunswieck as Vice President Cell & Gene Therapy

Celonic AG, the Swiss biologics contract development and manufacturing organization, has appointed Soenke Brunswieck as Vice President Cell & Gene Therapy to establish Celonic`s new …

Continue Reading →

Achieving Large-Scale Cell and Gene Therapy Manufacturing

Initial clinical successes with cell and gene therapies have driven significant investment in these next-generation technologies by both large bio/pharma companies and start-up specialist firms …

Continue Reading →

Sartorius Stedim Biotech Introduces Mini Microcarrier Bioreactor for Culturing Adherent Cells

New vessel for ambr® 250 ht system will enable cost-effective, scalable process development of vaccines in cell culture Premieres at the BPI European Summit in …

Continue Reading →